MRVI Strangle Strategy
MRVI (Maravai LifeSciences Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology.
MRVI (Maravai LifeSciences Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.72B, a beta of 0.71 versus the broader market, a 52-week range of 1.99-6.29, average daily share volume of 2.7M, a public-listing history dating back to 2020, approximately 570 full-time employees. These structural characteristics shape how MRVI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.71 places MRVI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on MRVI?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current MRVI snapshot
As of June 30, 2026, spot at $6.16, ATM IV 59.50%, IV rank 8.74%, expected move 17.06%. The strangle on MRVI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on MRVI specifically: MRVI IV at 59.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a MRVI strangle, with a market-implied 1-standard-deviation move of approximately 17.06% (roughly $1.05 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MRVI expiries trade a higher absolute premium for lower per-day decay. Position sizing on MRVI should anchor to the underlying notional of $6.16 per share and to the trader's directional view on MRVI stock.
MRVI strangle setup
The MRVI strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MRVI near $6.16, the first option leg uses a $6.47 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MRVI chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MRVI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.47 | N/A |
| Buy 1 | Put | $5.85 | N/A |
MRVI strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
MRVI strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on MRVI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on MRVI
Strangles on MRVI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MRVI chain.
MRVI thesis for this strangle
The market-implied 1-standard-deviation range for MRVI extends from approximately $5.11 on the downside to $7.21 on the upside. A MRVI long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current MRVI IV rank near 8.74% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on MRVI at 59.50%. As a Healthcare name, MRVI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MRVI-specific events.
MRVI strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MRVI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MRVI alongside the broader basket even when MRVI-specific fundamentals are unchanged. Always rebuild the position from current MRVI chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on MRVI?
- A strangle on MRVI is the strangle strategy applied to MRVI (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MRVI stock trading near $6.16, the strikes shown on this page are snapped to the nearest listed MRVI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are MRVI strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MRVI strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 59.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a MRVI strangle?
- The breakeven for the MRVI strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current MRVI market-implied 1-standard-deviation expected move is approximately 17.06%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on MRVI?
- Strangles on MRVI are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MRVI chain.
- How does current MRVI implied volatility affect this strangle?
- MRVI ATM IV is at 59.50% with IV rank near 8.74%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.